Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing
| Autor: | Jean-Paul Collet, Jean-Francois Boivin, Belzile E, L Abenhaim, Colin R. Sharpe, James A. Hanley |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Cancer Research
education.field_of_study medicine.medical_specialty business.industry Colorectal cancer Incidence (epidemiology) Population Cancer Rectum Regular Article colorectal cancer case–control studies medicine.disease Rate ratio Surgery medicine.anatomical_structure Oncology Internal medicine Cohort medicine non-steroidal anti-inflammatory drugs Adenocarcinoma epidemiology education business |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| DOI: | 10.1038/sj.bjc.6690651 |
| Popis: | Epidemiological studies show that non-steroidal anti-inflammatory drugs (NSAIDs) reduce colorectal cancer incidence. We measured the rate ratio for colorectal adenocarcinoma according to dosage and the timing of exposure by means of a case–control study, nested in a non-concurrent cohort linkage study, using the population of beneficiaries of the Saskatchewan Prescription Drug Plan from 1981 to 1995 with no history of cancer since 1970 as the source population. Four controls per case, matched on age and gender and alive when the case was diagnosed, were randomly selected. Dispensing rates, calculated over successive time periods, characterized NSAID exposure. We accrued 3844 cases of colon cancer and 1971 cases of rectal cancer. For colon cancer a significant trend towards a decreasing rate ratio was associated with increasing exposure during the 6 months preceding diagnosis (P-trend = 0.002). For both cancers, significant trends were associated with exposure 11–15 years before diagnosis (colon: P-trend = 0.01; rectum: P-trend = 0.0001). At the highest exposure levels the rate ratio for colon cancer was 0.57 (95% confidence interval (CI) 0.36–0.89); for rectal cancer it was 0.26 (95% CI 0.11–0.61). No protection was associated with exposure during other periods. The timing of NSAID use must be considered in planning intervention trials to prevent colorectal cancer. There may be a 10-year delay before any preventive effect will appear. © 1999 Cancer Research Campaign |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|